A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 209-217

  Fizazi, Karim ^a   Lesaunier, Francois ^b   Delva, Remy ^c   Gravis, Gwenaëlle ^d   Rolland, Frederic ^e   Priou, Frank ^f   Ferrero, Jean Marc ^g   Houedé, Nadine ^h   Mourey, Loïc ⁱ   Theodore, Christine ^j   Krakowski, Ivan ^k   Berdah, Jean Franois ^l   Baciuchka, Marjorie ^m   Laguerre, Brigitte ⁿ   Fléchon, Aude ^o   Ravaud, Alain ^p   Cojean Zelek, Isabelle ^q   Oudard, Stéphane ^r   Labourey, Jean Luc ^s   Lagrange, Jean Léon ^t   Chinet Charrot, Paule ^u   Linassier, Claude ^v   Deplanque, Gaël ^w   Beuzeboc, Philippe ^x   Geneve, Jean ^y   Davin, Jean Louis ^z   Tournay, Elodie ^a   Culine, Stephane ^aa   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Centre Franois Baclesse   (France)

^c CENTRE PAUL PAPIN   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f Centre Hospitalier Departemental   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

^j FOCH HOSPITAL   (France)

^k CENTRE ALEXIS VAUTRIN   (France)

^l Clinique Sainte Marguerite   (France)

^m TIMONE HOSPITAL   (France)

ⁿ Centre Eugne Marquis   (France)

^o CENTRE LÉON BÉRARD   (France)

^p HÔPITAL SAINT ANDRÉ   (France)

^q GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^r HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^s DUPUYTREN UNIVERSITY HOSPITAL   (France)

^t HENRI MONDOR HOSPITAL   (France)

^u CENTRE HENRI BECQUEREL   (France)

^v Paris 5 Descartes University EA 2496 U F R of Odontology   (France)

^w SAINT JOSEPH HOSPITAL   (France)

^x INSTITUT CURIE   (France)

^y FNCLCC   (France)

^z INSTITUT SAINTE CATHERINE   (France)

^aa SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Docetaxel; Estramustine; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; DOCETAXEL; ESTRAMUSTINE; GOSERELIN; PREDNISONE; WARFARIN;

ADULT; AGED; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GLEASON SCORE; HEALTH STATUS; HOT FLUSH; HUMAN; INFECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SOCIAL INTERACTION; THROMBOSIS; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ESTRAMUSTINE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 84655167067     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.015     Document Type: Article

References (51)

1. J. Ferlay, P. Autier, and M. Boniol Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005 7012
4. C.T. Nguyen, A.M. Reuther, A.J. Stephenson, E.A. Klein, and J.S. Jones The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival J Urol 181 2009 75 80
5. A.V. D'Amico, K. Cote, M. Loffredo, A.A. Renshaw, and D. Schultz Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 2002 4567 4573 (Pubitemid 35402960)
6. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
7. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
8. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591 (Pubitemid 351264352)
9. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
10. A.V. D'Amico, J. Manola, and M. Loffredo Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
11. J.W. Denham, A. Steigler, and D.S. Lamb Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850 (Pubitemid 41614795)
12. A. Widmark, O. Klepp, and A. Solberg Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308 [Erratum in: Lancet 2009;373:1174]
13. M. Bolla, T.M. de Reijke, and G. Van Tienhoven EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
14. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373 (Pubitemid 350232211)
15. M. Roach 3rd, M. DeSilvio, and C. Lawton Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
16. P.L. Nguyen, and A.V. D'Amico Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials J Clin Oncol 26 2008 2055 2056
17. E.M. Messing, J. Manola, and J. Yao Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479 (Pubitemid 43779173)
18. C.A. Lawton, K. Winter, D. Grignon, and M.V. Pilepich Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 J Clin Oncol 23 2005 800 807 [Erratum in: J Clin Oncol 2005;23:8921] (Pubitemid 46224179)
19. Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2009 [Epub ahead of print].
20. K. Fizazi, C.R. Sikes, and J. Kim High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer Anticancer Res 24 2004 2897 2903 (Pubitemid 39407164)
21. D.P. Petrylak, R.B. Macarthur, and J. O'Connor Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer J Clin Oncol 17 1999 958 967 (Pubitemid 29109329)
22. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
23. I.F. Tannock, R. de Wit, and W.R. Berry TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
24. K. Fizazi, A. Le Maitre, and G. Hudes Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data Lancet Oncol 8 2007 994 1000 (Pubitemid 47629887)
25. V. Beckendorf, S. Guérif, and E. Le Prisé The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity Int J Radiat Oncol Biol Phys 1560 2004 1056 1065 (Pubitemid 39440789)
26. ICRU. ICRU Report 50: Prescribing, recording and reporting photon beam therapy. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
27. ICRU. ICRU Report 62: Prescribing, recording and reporting photon beam therapy. (Supplement to ICRU report 50). Bethesda; 1999.
28. W.U. Shipley, L.J. Verhey, and J.E. Munzenrider Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone Int J Radiat Oncol Biol Phys 32 1995 3 12
29. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
30. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
31. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
32. R. de Crevoisier, S.L. Tucker, and L. Dong Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy Int J Radiat Oncol Biol Phys 62 2005 965 973 (Pubitemid 40884405)
33. J.S. de Bono, S. Oudard, and M. Ozguroglu TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
34. S.M. Scholl, A. Fourquet, and B. Asselain Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 Eur J Cancer 30A 1994 645 652 (Pubitemid 24164252)
35. B.J. Eigl, S.E. Eggener, and J. Baybik Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer Clin Cancer Res 11 2005 4905 4911 (Pubitemid 41557211)
36. K. Fizazi, C.R. Sikes, and J. Kim High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer Anticancer Res 24 2004 2897 2903 (Pubitemid 39407164)
37. K.S. Albain, W.E. Barlow, and P.M. Ravdin Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 2055 2063
38. G. Hudes Estramustine-based chemotherapy Semin Urol Oncol 15 1997 13 19 (Pubitemid 27091622)
39. B. Dahllof, A. Billstrom, F. Cabral, and B. Hartley-Asp Estramustine depolymerizes microtubules by binding to tubulin Cancer Res 53 1993 4573 4581 (Pubitemid 23304382)
40. N. Laing, B. Dahllof, B. Hartley-Asp, S. Ranganathan, and K.D. Tew Interaction of estramustine with tubulin isotypes Biochemistry 36 1997 871 878 (Pubitemid 27110968)
41. L.A. Speicher, N. Laing, and L.R. Barone Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells Mol Pharmacol 46 1994 866 872 (Pubitemid 24364098)
42. J.C. Eymard, F. Priou, and A. Zannetti Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer Ann Oncol 18 2007 1064 1070 (Pubitemid 47050499)
43. K. Fizazi, A. Le Maitre, and G. Hudes Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data Lancet Oncol 8 2007 994 1000 (Pubitemid 47629887)
44. S.A. Rosenthal, K. Bae, and K.J. Pienta Radiation Therapy Oncology Group Trial 9902. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02 Int J Radiat Oncol Biol Phys 73 2009 672 678
45. T.W. Flaig, C.M. Tangen, and M.H. Hussain Southwest Oncology Group. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial J Clin Oncol 26 2008 1532 1536
46. M.J. Zelefsky, O. Lyass, and Z. Fuks Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy J Clin Oncol 16 1998 3380 3385 (Pubitemid 28481636)
47. R. de Crevoisier, K. Slimane, and T. Messai Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy Ann Oncol 21 2010 808 814
48. A. Alexander, J. Crook, and S. Jones Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial Int J Radiat Oncol Biol Phys 76 2010 23 30
49. J.D. Schmidt, R.P. Gibbons, G.P. Murphy, and A. Bartolucci Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project Prostate 28 1996 51 57 (Pubitemid 26035442)
50. J. Wang, S. Halford, and A. Rigg Adjuvant mitoxantrone chemotherapy in advanced prostate cancer BJU Int 86 2000 675 680
51. H.M. Sandler, D. Hunt, and A.O. Sartor A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902 Proc Am Soc Clin Oncol 28 2010 374s (Abstr 4632)